참고문헌
- Labarthe DR, Dunbar SB. Global cardiovascular health promotion and disease prevention: 2011 and beyond. Circulation 2012;125:2667-2676. https://doi.org/10.1161/CIRCULATIONAHA.111.087726
- World Health Organization. Cardiovascular diseases (CVDs) [Internet]. Geneva: World Health Organization, 2017 [cited 2021 Mar 23]. Available from: https://www.who.int/en/newsroom/fact-sheets/detail/cardiovascular-diseases-(cvds).
- Sanyaolu A, Okorie C, Marinkovic A, Patidar R, Younis K, Desai P, et al. Comorbidity and its impact on patients with COVID-19. SN Compr Clin Med 2020;2:1069-1076. https://doi.org/10.1007/s42399-020-00363-4
- British Heart Foundation. Cardiovascular disease (CVD): types, causes and symptoms [Internet]. Birmingham: British Heart Foundation, 2019 [cited 2021 Mar 23]. Available from: https://www.bhf.org.uk/informationsupport/conditions/cardiovascular-heart-disease.
- Yeates K, Lohfeld L, Sleeth J, Morales F, Rajkotia Y, Ogedegbe O. A global perspective on cardiovascular disease in vulnerable populations. Can J Cardiol 2015;31:1081-1093. https://doi.org/10.1016/j.cjca.2015.06.035
- Kreatsoulas C, Anand SS. The impact of social determinants on cardiovascular disease. Can J Cardiol 2010;26 Suppl C:8C-13C. https://doi.org/10.1016/S0828-282X(10)71075-8
- Cambien F, Tiret L. Genetics of cardiovascular diseases: from single mutations to the whole genome. Circulation 2007;116:1714-1724. https://doi.org/10.1161/CIRCULATIONAHA.106.661751
- Morrison N, Cochrane G, Faruque N, Tatusova T, Tateno Y, Hancock D, et al. Concept of sample in OMICS technology. OMICS 2006;10:127-137. https://doi.org/10.1089/omi.2006.10.127
- Heart disease [Internet]. Rochester: Mayo Clinic, 2021 [cited 2021 Mar 23]. Available from: https://www.mayoclinic.org/diseases-conditions/heart-disease/symptoms-causes/syc-20353118?p=1.
- Aboughdir M, Kirwin T, Abdul Khader A, Wang B. Prognostic value of cardiovascular biomarkers in COVID-19: a review. Viruses 2020;12:527. https://doi.org/10.3390/v12050527
- Yancy CW, Benjamin EJ, Fabunmi RP, Bonow RO. Discovering the full spectrum of cardiovascular disease: Minority Health Summit 2003: executive summary. Circulation 2005;111:1339-1349. https://doi.org/10.1161/01.CIR.0000157740.93598.51
- Horgan RP, Kenny LC. 'Omic' technologies: genomics, transcriptomics, proteomics and metabolomics. Obstet Gynaecol 2011; 13:189-195. https://doi.org/10.1576/toag.13.3.189.27672
- Schneider MV, Orchard S. Omics technologies, data and bioinformatics principles. Methods Mol Biol 2011;719:3-30. https://doi.org/10.1007/978-1-61779-027-0_1
- Ussher JR, Elmariah S, Gerszten RE, Dyck JR. The emerging role of metabolomics in the diagnosis and prognosis of cardiovascular disease. J Am Coll Cardiol 2016;68:2850-2870. https://doi.org/10.1016/j.jacc.2016.09.972
- Azuaje F, Devaux Y, Wagner D. Computational biology for cardiovascular biomarker discovery. Brief Bioinform 2009;10:367-377. https://doi.org/10.1093/bib/bbp008
- Shameer K, Badgeley MA, Miotto R, Glicksberg BS, Morgan JW, Dudley JT. Translational bioinformatics in the era of real-time biomedical, health care and wellness data streams. Brief Bioinform 2017;18:105-124. https://doi.org/10.1093/bib/bbv118
- Gottesman O, Scott SA, Ellis SB, Overby CL, Ludtke A, Hulot JS, et al. The CLIPMERGE PGx Program: clinical implementation of personalized medicine through electronic health records and genomics-pharmacogenomics. Clin Pharmacol Ther 2013;94: 214-217. https://doi.org/10.1038/clpt.2013.72
- Haarbrandt B, Tute E, Marschollek M. Automated population of an i2b2 clinical data warehouse from an openEHR-based data repository. J Biomed Inform 2016;63:277-294. https://doi.org/10.1016/j.jbi.2016.08.007
- Woo A, Rakowski H, Liew JC, Zhao MS, Liew CC, Parker TG, et al. Mutations of the beta myosin heavy chain gene in hypertrophic cardiomyopathy: critical functional sites determine prognosis. Heart 2003;89:1179-1185. https://doi.org/10.1136/heart.89.10.1179
- Roberts R, Marian AJ, Dandona S, Stewart AF. Genomics in cardiovascular disease. J Am Coll Cardiol 2013;61:2029-2037. https://doi.org/10.1016/j.jacc.2012.12.054
- Podgoreanu MV, Schwinn DA. Genomics and the circulation. Br J Anaesth 2004;93:140-148. https://doi.org/10.1093/bja/aeh168
- Podgoreanu MV, Schwinn DA. New paradigms in cardiovascular medicine: emerging technologies and practices: perioperative genomics. J Am Coll Cardiol 2005;46:1965-1977. https://doi.org/10.1016/j.jacc.2005.08.040
- Liew CC, Dzau VJ. Molecular genetics and genomics of heart failure. Nat Rev Genet 2004;5:811-825. https://doi.org/10.1038/nrg1470
- Graves PR, Haystead TA. Molecular biologist's guide to proteomics. Microbiol Mol Biol Rev 2002;66:39-63. https://doi.org/10.1128/MMBR.66.1.39-63.2002
- Yates JR 3rd. Mass spectrometry and the age of the proteome. J Mass Spectrom 1998;33:1-19. https://doi.org/10.1002/(SICI)1096-9888(199801)33:1<1::AID-JMS624>3.0.CO;2-9
- Qin J, Fenyo D, Zhao Y, Hall WW, Chao DM, Wilson CJ, et al. A strategy for rapid, high-confidence protein identification. Anal Chem 1997;69:3995-4001. https://doi.org/10.1021/ac970488v
- Muller EC, Thiede B, Zimny-Arndt U, Scheler C, Prehm J, Muller-Werdan U, et al. High-performance human myocardial two-dimensional electrophoresis database: edition 1996. Electrophoresis 1996;17:1700-1712. https://doi.org/10.1002/elps.1150171107
- Dunn MJ. Studying heart disease using the proteomic approach. Drug Discov Today 2000;5:76-84. https://doi.org/10.1016/S1359-6446(99)01449-X
- Wu AH. Early detection of acute coronary syndromes and risk stratification by multimarker analysis. Biomark Med 2007;1:45-57. https://doi.org/10.2217/17520363.1.1.45
- Tu WJ, Liu Q, Cao JL, Zhao SJ, Zeng XW, Deng AJ. Gamma-glutamyl transferase as a risk factor for all-cause or cardiovascular disease mortality among 5912 ischemic stroke. Stroke 2017;48: 2888-2891. https://doi.org/10.1161/STROKEAHA.117.017776
- Anderson L. Candidate-based proteomics in the search for biomarkers of cardiovascular disease. J Physiol 2005;563:23-60. https://doi.org/10.1113/jphysiol.2004.080473
- Fu Q, Van Eyk JE. Proteomics and heart disease: identifying biomarkers of clinical utility. Expert Rev Proteomics 2006;3:237-249. https://doi.org/10.1586/14789450.3.2.237
- Mayr M, Zhang J, Greene AS, Gutterman D, Perloff J, Ping P. Proteomics-based development of biomarkers in cardiovascular disease: mechanistic, clinical, and therapeutic insights. Mol Cell Proteomics 2006;5:1853-1864. https://doi.org/10.1074/mcp.R600007-MCP200
- Arnett DK, Claas SA. Omics of Blood Pressure and Hypertension. Circ Res 2018;122:1409-1419. https://doi.org/10.1161/CIRCRESAHA.118.311342
- Gomes CP, Agg B, Andova A, Arslan S, Baker A, Bartekova M, et al. Catalyzing transcriptomics research in cardiovascular disease: the CardioRNA COST Action CA17129. Noncoding RNA 2019; 5:31.
- Wu PY, Chandramohan R, Phan JH, Mahle WT, Gaynor JW, Maher KO, et al. Cardiovascular transcriptomics and epigenomics using next-generation sequencing: challenges, progress, and opportunities. Circ Cardiovasc Genet 2014;7:701-710. https://doi.org/10.1161/CIRCGENETICS.113.000129
- Zhou SS, Jin JP, Wang JQ, Zhang ZG, Freedman JH, Zheng Y, et al. miRNAS in cardiovascular diseases: potential biomarkers, therapeutic targets and challenges. Acta Pharmacol Sin 2018;39: 1073-1084. https://doi.org/10.1038/aps.2018.30
- Alavi-Moghaddam M, Chehrazi M, Alipoor SD, Mohammadi M, Baratloo A, Mahjoub MP, et al. A Preliminary study of microRNA-208b after acute myocardial infarction: impact on 6-month survival. Dis Markers 2018;2018:2410451. https://doi.org/10.1155/2018/2410451
- Rath M, Pauling L. A unified theory of human cardiovascular disease leading the way to the abolition of this disease as a cause for human mortality. J Orthomol Med 1992;7:5-15.
- Tahir UA, Gerszten RE. Omics and cardiometabolic disease risk prediction. Annu Rev Med 2020;71:163-175. https://doi.org/10.1146/annurev-med-042418-010924
- Senn T, Hazen SL, Tang WH. Translating metabolomics to cardiovascular biomarkers. Prog Cardiovasc Dis 2012;55:70-76. https://doi.org/10.1016/j.pcad.2012.06.004
- Polonis K, Wawrzyniak R, Daghir-Wojtkowiak E, Szyndler A, Chrostowska M, Melander O, et al. Metabolomic signature of early vascular aging (EVA) in hypertension. Front Mol Biosci 2020;7:12. https://doi.org/10.3389/fmolb.2020.00012
- McGarrah RW, Crown SB, Zhang GF, Shah SH, Newgard CB. Cardiovascular metabolomics. Circ Res 2018;122:1238-1258. https://doi.org/10.1161/CIRCRESAHA.117.311002
- Lewis GD, Asnani A, Gerszten RE. Application of metabolomics to cardiovascular biomarker and pathway discovery. J Am Coll Cardiol 2008;52:117-123. https://doi.org/10.1016/j.jacc.2008.03.043